ORIGINAL RESEARCH article
Front. Public Health
Sec. Health Economics
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1646950
This article is part of the Research TopicIntegrating Economics into Population Health: Assessing Policies and OutcomesView all 14 articles
Estimation of the current healthcare costs of gout in Liaoning Province from 2015 to 2022 based on the SHA2011 accounting system
Provisionally accepted
- 1Guangzhou University of Chinese Medicine, Guangzhou, China
- 2Liaoning Health Economics Association, Shenyang,China, China
- 3China National Health Development Research Center, Beijing, China
- 4Liaoning University of Traditional Chinese Medicine, Shenyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Gout has become a major public health problem worldwide, causing severe pain, discomfort, inflammation, mobility problems and impaired physical functioning, resulting in heavy economic losses and social burdens. Methods: The study was based on System of Health Accounts 2011 (SHA 2011) and data of 97907 patients from 1084 healthcare organizations were taken using multistage stratified random sampling method. Descriptive analysis of therapeutic care expenditures (CCE), Sankey diagram to analyze the flow of CCE, Mann-Whitney U test to analyze 2 independent samples, Kruskal-Wallis H to analyze K independent samples significance. Multifactorial analysis of CCE influences, Structural Equation Modeling (SEM) to analyze the direct and indirect effects and mediating role. Results: CCE increases from CNY 25.32 million in 2015 to CNY 116.02 million in 2022, with a concentration of ages 30-69. The proportion of public health financing decreases with age and is dominated by general hospitals. The difference is significant in single-factor analysis, and the high cost in multi-factor analysis is related to purchase drugs, elective treatment, basic medical insurance for urban and rural residents, provincial level, Chinese medicine hospitals, and large standardized coefficients in 2020, and outpatient/inpatient care, drugs, type of institution, insurance status, and gender by path coefficients in the SEM in the order of directly or indirectly affecting the CCE. Conclusion: Gout disease in Liaoning Province imposes a heavy financial burden on patients and the health insurance system. It is recommended to increase reimbursement for gout inpatient costs, improve primary care guidelines and purinol dose adherence, strengthen primary care collaborative personalized education and care to achieve uric acid-lowering effects, increase subsidies and inclusion of gout prescription medications in the local health insurance directory, and for men to reduce consumption of high-purine foods and alcohol at social events.
Keywords: Gout, Direct medical expenditure, Medical service utilization, SHA2011, social health insurance
Received: 17 Jun 2025; Accepted: 01 Sep 2025.
Copyright: © 2025 Shi, Zheng, Wan, Chai, Wang, Pang and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhenmiao Pang, Guangzhou University of Chinese Medicine, Guangzhou, China
Yuedan Ma, Liaoning University of Traditional Chinese Medicine, Shenyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.